AChE inhibitors and substrates

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
'''Dear readers, this page presents only a small part of the great world of the acetylcholinesterase inhibitors. So, please see also our pages [[AChE inhibitors and substrates (Part II)]], [[AChE bivalent inhibitors]] and [[AChE bivalent inhibitors (Part II)]].'''
+
'''Dear readers, this page presents only a small part of the great world of the acetylcholinesterase inhibitors. So, please see also our pages [[AChE inhibitors and substrates (Part II)]], [[AChE inhibitors and substrates (Part III)]], [[AChE bivalent inhibitors]] and [[AChE bivalent inhibitors (Part II)]].'''
{{Clear}}
{{Clear}}
==AChE substrate==
==AChE substrate==
Line 14: Line 14:
==AChE monovalent inhibitors (Part I)==
==AChE monovalent inhibitors (Part I)==
-
[http://en.wikipedia.org/wiki/Alzheimer's_disease Alzheimer's disease] (AD) is a disorder that attacks the [http://en.wikipedia.org/wiki/Central_nervous_system central nervous system] through progressive degeneration of its neurons. Patients with this disease develop [http://en.wikipedia.org/wiki/Dementia dementia] which becomes more severe as the disease progresses. It was suggested that symptoms of AD are caused by decrease of activity of [http://en.wikipedia.org/wiki/Cholinergic cholinergic] [http://en.wikipedia.org/wiki/Neocortex neocortical] and [http://en.wikipedia.org/wiki/Hippocampus hippocampal] neurons. Treatment of AD by ACh precursors and [http://en.wikipedia.org/wiki/Cholinergic cholinergic] [http://en.wikipedia.org/wiki/Agonist agonists] was ineffective or caused severe side effects. ACh hydrolysis by AChE causes termination of cholinergic neurotransmission. Therefore, compounds which inhibit AChE might significantly increase the levels of ACh depleted in AD. Indeed, it was shown that [http://en.wikipedia.org/wiki/Acetylcholinesterase_inhibitor AChE inhibitors] improve the cognitive abilities of AD patients at early stages of the disease development. The first generation of AD drugs were AChE inhibitors: alcaloids like [http://en.wikipedia.org/wiki/Huperzine_A (-)-Huperzine A (HupA)] and [http://en.wikipedia.org/wiki/Galantamine (-)-galanthamine (GAL, Reminyl)]; [http://en.wikipedia.org/wiki/Chemical_synthesis synthetic] compounds [http://en.wikipedia.org/wiki/Tacrine tacrine (Cognex)] and [http://en.wikipedia.org/wiki/Rivastigmine rivastigmine (Exelon)].
+
'''Organophosphorus acid anhydride nerve agents'''
-
{{Clear}}
+
-
 
+
-
+
-
[[Image:HuperzineA3.jpg|left|250px]]
+
-
'''1)''' [http://en.wikipedia.org/wiki/Huperzine_A (-)-Huperzine A], discovered by Chinese scientists from 1980s, has been proved to be a powerful, highly specific, and [http://en.wikipedia.org/wiki/Enzyme_inhibitor#Reversible_inhibitors reversible inhibitor] of AChE. It is a novel [http://en.wikipedia.org/wiki/Alkaloid alkaloid] originally isolated from the '''Traditional Chinese medicine''' [http://en.wikipedia.org/wiki/Traditional_Chinese_medicine] Qian Ceng Ta which is produced from the whole plant of the [http://en.wikipedia.org/wiki/Firmoss firmoss][http://en.wikipedia.org/wiki/Huperzia_serrata ''Huperzia serrata'']. Qian Ceng Ta has been used for over 1000 years in China for treatment of [http://en.wikipedia.org/wiki/Bruise contusions], [http://en.wikipedia.org/wiki/Strain_(injury) strains], [http://en.wikipedia.org/wiki/Swelling_(medical) swellings], [http://en.wikipedia.org/wiki/Schizophrenia schizophrenia] and [http://en.wikipedia.org/wiki/Myasthenia_gravis myasthenia gravis]. Shuangyiping[http://www.54md.com/drugstore/pic/gpic_25fd25197010a0fb4a680516735e613c.jpg], a tablet form of HupA produced from the extracts of ''Huperzia serrata'', was developed in 1996 as a new drug for symptomatic treatment of Alzheimer’s disease in China. Compared with the other three [http://en.wikipedia.org/wiki/Food_and_Drug_Administration_(United_States) FDA]-approved drugs for the treatment of Alzheimer’s disease, Donepezil (Aricept), Rivastigmine (Exelon), Galanthamine (Reminyl), HupA has better penetration through the [http://en.wikipedia.org/wiki/Blood-brain_barrier blood-brain barrier], higher oral [http://en.wikipedia.org/wiki/Bioavailability bioavailability], and longer duration of AChE inhibitory action. The structure of HupA shows some similarity to other known AChE inhibitors. The molecule is fairly rigid and contains an [http://en.wikipedia.org/wiki/Aromaticity aromatic] system as well as a [http://en.wikipedia.org/wiki/Amine primary amino group] that is probably [http://en.wikipedia.org/wiki/Protonation protonated] at physiological [http://en.wikipedia.org/wiki/PH pH]. Various suggestions have been made with respect to its orientation within the active site of AChE, and with respect to the amino acid residue with which its putative [http://en.wikipedia.org/wiki/Pharmacophore pharmacophoric] groups might interact. Solution of the 3D structure of a complex of HupA with AChE would permit unequivocal resolution of this issue and it would also provide a rational basis for structure-related [http://en.wikipedia.org/wiki/Drug_design drug design] aimed at developing synthetic analogues of HupA with improved therapeutic properties.
+
-
 
+
-
<applet load='1vot' size='500' frame='true' align='right'
+
-
scene='1vot/Com_view/1' />
+
-
The [http://en.wikipedia.org/wiki/X-ray_crystallography crystal structure] of the complex of ''Tc''AChE with HupA at 2.5 Å resolution ([[1vot]]) was determined in 1997 and it shows an unexpected orientation for the inhibitor with surprisingly few strong direct interactions with protein residues to explain its high affinity. <font color='blueviolet'><b>HupA</b></font> binds to ''Tc''AChE at the active site, and its <scene name='1vot/Active_site/8'>observed orientation is almost orthogonal</scene> in comparison to <font color='gray'><b>ACh</b></font>. The principal interactions of <scene name='1vot/1vot_ache_interactions/2'>HupA with TcAChE</scene> are including: a direct <scene name='1vot/1vot_199_130_117/2'>hydrogen bond with Tyr130 and HBs with Glu199 and Gly117 </scene> <font color='orange'><b>(colored orange)</b></font> through a water molecule as a linker at the bottom of the gorge; [http://en.wikipedia.org/wiki/Cation-pi_interaction cation-π] interactions between the amino group of <scene name='1vot/1vot_84_330/2'>HupA and Trp84 and Phe330</scene> <font color='lime'><b>(colored lime)</b></font> with the distance between the nitrogen and the centroid of the aromatic rings of 4.8 and 4.7 Å, respectively; at the top of the gorge, [http://en.wikipedia.org/wiki/Hydrogen_bond hydrogen bonds] through two water molecules as linkers formed between the amino group of <scene name='1vot/1vot_70_72_81_85_121/3'>HupA and Tyr70, Asp72, Ser81, Asn85 and Tyr121</scene> <font color='magenta'><b>(colored magenta)</b></font>. An unusually short (~3.0 Å) C-H→O HB has been seen between the ethylidene methyl group of <scene name='1vot/1vot_440/2'>HupA and the main chain oxygen of His440</scene> <font color='crimson'><b>(colored crimson)</b></font>.
 
{{Clear}}
{{Clear}}
-
<applet load='ACHE2.pdb' size='500' frame='true' align='left'
+
[http://en.wikipedia.org/wiki/Organophosphorus Organophosphorus] (OP) [http://en.wikipedia.org/wiki/Acid_anhydride acid anhydride] [http://en.wikipedia.org/wiki/Nerve_agent nerve agents] are potent inhibitors which rapidly phosphonylate AChE and then may undergo an internal dealkylation reaction (called "aging") to produce an OP-enzyme conjugate that cannot be reactivated.
-
scene='AChE_inhibitors_and_substrates/Com_view_tacrine/1' />
+
-
 
+
-
'''2)''' [http://en.wikipedia.org/wiki/Tacrine Tacrine]. In the X-ray crystal structure of ''Tc''AChE/<scene name='AChE_inhibitors_and_substrates/Com_view_tacrine/2'>tacrine</scene> complex which was determined at 2.8 Å resolution, the tacrine is seen <font color='magenta'><b>(magenta)</b></font> bound in the active site of ''Tc''AChE ([[1acj]]) . <font color='gray'><b>ACh (gray)</b></font> is shown for comparison.
+
-
{{Clear}}
+
-
 
+
-
<applet load='AC3.pdb' size='500' frame='true' align='right'
+
-
scene='1e66/Active_site/1' />
+
-
 
+
-
'''3)''' <scene name='1e66/Active_site/2'>Huprine X</scene> ('''HUP'''erzine A + tac'''RINE''') is one of the most potent [http://en.wikipedia.org/wiki/Acetylcholinesterase_inhibitor#Reversible_inhibitor reversible AChE inhibitors]. This synthetic hybrid consists of a carbobicyclic moiety resembling that of (−)-<scene name='1e66/Active_site/12'>huperzine A</scene> <font color='blueviolet'><b>(colored blueviolet)</b></font> and the [http://en.wikipedia.org/wiki/4-Aminoquinoline 4-aminoquinoline] substructure of <scene name='1e66/Active_site/7'>tacrine</scene> <font color='magenta'><b>(colored magenta)</b></font>. Both these compounds are known AChE inhibitors. <font color='blueviolet'><b>(−)-Huperzine A</b></font> and <font color='magenta'><b>tacrine</b></font> positions partially overlap each other at the ''Tc''AChE <scene name='1e66/Active_site/13'>active site</scene>. ''Tc''AChE residues interacting with (−)-huperzine A ([[1vot]]) <font color='orange'><b>are colored orange</b></font> and with tacrine ([[1acj]]) <font color='cyan'><b>are colored cyan</b></font>. The <scene name='1e66/Active_site/10'>conformation</scene> of the 4-aminoquinoline substructure of the huprine X in its complex with ''Tc''AChE ([[1e66]], ''Tc''AChE interacting residues are in <font color='lime'><b>lime</b></font>) is very similar to that of tacrine. The ring system of (−)-huperzine A is <scene name='1e66/Active_site/14'>rotated</scene> almost 180° relative to that of huprine X.
+
-
{{Clear}}
+
-
 
+
-
{{Clear}}
+
-
 
+
-
'''4)''' [http://en.wikipedia.org/wiki/Organophosphorus Organophosphorus] (OP) [http://en.wikipedia.org/wiki/Acid_anhydride acid anhydride] [http://en.wikipedia.org/wiki/Nerve_agent nerve agents] are potent inhibitors which rapidly phosphonylate AChE and then may undergo an internal dealkylation reaction (called "aging") to produce an OP-enzyme conjugate that cannot be reactivated.
+
[[Image:Soman_reaction.png | left | thumb | 800px | Reaction between Ser200Oγ and Soman, assuming an in-line attack by the Oγ, followed by spontaneous dealkylation of the O-pinacolyl group.]]
[[Image:Soman_reaction.png | left | thumb | 800px | Reaction between Ser200Oγ and Soman, assuming an in-line attack by the Oγ, followed by spontaneous dealkylation of the O-pinacolyl group.]]
<br style="clear:both;"/>
<br style="clear:both;"/>
{{Clear}}
{{Clear}}
 +
<applet load='Soman1.pdb' size='500' frame='true' align='right' scene='2wfz/Al/1' />
<applet load='Soman1.pdb' size='500' frame='true' align='right' scene='2wfz/Al/1' />
 +
As was mentioned above, AChE hydrolysizes the neurotransmitter <scene name='2wfz/Al/2'>ACh</scene>, producing <scene name='2wfz/Al/3'>choline and an acetate</scene> group. <scene name='2wfz/Al/2'>ACh</scene> directly binds catalytic <scene name='2wfz/Al/4'>Ser200</scene> (via its nucleophilic Oγ atom). <scene name='2wfz/Al/5'>Soman</scene>, [http://en.wikipedia.org/wiki/Soman O-(1,2,2-trimethylpropyl) methylphosphonofluoridate] (<font color='violet'><b>fluorine atom is colored violet</b></font> and <font color='darkmagenta'><b>phosphorus atom is colored darkmagenta</b></font>), is one of the most toxic OPs. Soman inhibits AChE by <scene name='2wfz/Al/6'>covalent binding</scene> to catalytic Ser200, <scene name='2wfz/Al/7'>mimicking ACh</scene>. This process <scene name='2wfz/Al/8'>(phosphonylation)</scene> implicates nucleophilic attack of the Ser200 nucleophilic Oγ atom on the phosphorus atom of soman, with concomitant departure of its fluoride atom. After that AChE catalyzes the <scene name='2wfz/Al/9'>dealkylation ("aging")</scene> of the soman or other OP. This causes irreversible inhibition of AChE, "aged" soman/AChE conjugate can not be reactivated. However, before “aging”, at the step of <scene name='2wfz/Al/8'>phosphonylation</scene>, AChE can be <scene name='2wfz/Al/11'>reactivated</scene> by nucleophiles, such as pralidoxime (2-PAM), resulting in <scene name='2wfz/Al/12'>cleavage</scene> of the phosphonyl adduct from Ser200 Oγ.
As was mentioned above, AChE hydrolysizes the neurotransmitter <scene name='2wfz/Al/2'>ACh</scene>, producing <scene name='2wfz/Al/3'>choline and an acetate</scene> group. <scene name='2wfz/Al/2'>ACh</scene> directly binds catalytic <scene name='2wfz/Al/4'>Ser200</scene> (via its nucleophilic Oγ atom). <scene name='2wfz/Al/5'>Soman</scene>, [http://en.wikipedia.org/wiki/Soman O-(1,2,2-trimethylpropyl) methylphosphonofluoridate] (<font color='violet'><b>fluorine atom is colored violet</b></font> and <font color='darkmagenta'><b>phosphorus atom is colored darkmagenta</b></font>), is one of the most toxic OPs. Soman inhibits AChE by <scene name='2wfz/Al/6'>covalent binding</scene> to catalytic Ser200, <scene name='2wfz/Al/7'>mimicking ACh</scene>. This process <scene name='2wfz/Al/8'>(phosphonylation)</scene> implicates nucleophilic attack of the Ser200 nucleophilic Oγ atom on the phosphorus atom of soman, with concomitant departure of its fluoride atom. After that AChE catalyzes the <scene name='2wfz/Al/9'>dealkylation ("aging")</scene> of the soman or other OP. This causes irreversible inhibition of AChE, "aged" soman/AChE conjugate can not be reactivated. However, before “aging”, at the step of <scene name='2wfz/Al/8'>phosphonylation</scene>, AChE can be <scene name='2wfz/Al/11'>reactivated</scene> by nucleophiles, such as pralidoxime (2-PAM), resulting in <scene name='2wfz/Al/12'>cleavage</scene> of the phosphonyl adduct from Ser200 Oγ.
At the <scene name='2wfz/Ali/3'>active site of the nonaged soman/TcAChE conjugate</scene> ([[2wfz]]) the catalytic His440 forms hydrogen bonds with Ser200 Oγ and Glu327 Oε1 via its Nε2 and Nδ1 nitrogens, respectively. The O2 atom of soman is within hydrogen bonding distance of His440 Nε2. Soman O1 mimicks carbonyl oxygen of ACh. A water molecule 1001 interacting with soman O2 is represented as a <font color='red'><b>red ball</b></font>. The active site residues of the nonaged soman/TcAChE are colored <font color='yellow'><b>yellow</b></font>. The O2 atom of the <scene name='2wfz/Ali/4'>dealkylated (aged) soman</scene> ([[2wg0]]) forms a salt bridge with His440 Nε2. The active site residues of the aged soman/TcAChE are colored <font color='pink'><b>pink</b></font>. <scene name='2wfz/Ali/5'>Alignment</scene> of the structures of the nonaged ([[2wfz]]) and aged ([[2wg0]]) conjugates reveals a small, but important, change within the active site - the imidazole ring of His440 is tilted back to a native-like conformation after dealkylation. The water molecule 1001, which interacts with soman O2 in the nonaged crystal structure, is not within hydrogen bonding distance of O2 in the aged crystal structure. 2-PAM binds poorly to the nonaged phosphonylated enzyme (its electron density was not found) and binds in an <scene name='2wfz/Ali/7'>unfavorable and nonfunctional conformation</scene> after soman aging to ''Tc''AChE ([[2wg1]]).
At the <scene name='2wfz/Ali/3'>active site of the nonaged soman/TcAChE conjugate</scene> ([[2wfz]]) the catalytic His440 forms hydrogen bonds with Ser200 Oγ and Glu327 Oε1 via its Nε2 and Nδ1 nitrogens, respectively. The O2 atom of soman is within hydrogen bonding distance of His440 Nε2. Soman O1 mimicks carbonyl oxygen of ACh. A water molecule 1001 interacting with soman O2 is represented as a <font color='red'><b>red ball</b></font>. The active site residues of the nonaged soman/TcAChE are colored <font color='yellow'><b>yellow</b></font>. The O2 atom of the <scene name='2wfz/Ali/4'>dealkylated (aged) soman</scene> ([[2wg0]]) forms a salt bridge with His440 Nε2. The active site residues of the aged soman/TcAChE are colored <font color='pink'><b>pink</b></font>. <scene name='2wfz/Ali/5'>Alignment</scene> of the structures of the nonaged ([[2wfz]]) and aged ([[2wg0]]) conjugates reveals a small, but important, change within the active site - the imidazole ring of His440 is tilted back to a native-like conformation after dealkylation. The water molecule 1001, which interacts with soman O2 in the nonaged crystal structure, is not within hydrogen bonding distance of O2 in the aged crystal structure. 2-PAM binds poorly to the nonaged phosphonylated enzyme (its electron density was not found) and binds in an <scene name='2wfz/Ali/7'>unfavorable and nonfunctional conformation</scene> after soman aging to ''Tc''AChE ([[2wg1]]).
Line 66: Line 45:
DFP, di''iso''propylphosphorofluoridate, is an other toxic OP nerve agent. It is also inhibits AChE by covalent binding to the catalytic Ser200. As in the case with soman ([[1som]]) and sarin ([[1cfj]]), there are four hydrogen bond donors (dotted lines) to the anionic phosphonyl oxygen atoms: the backbone amide nitrogen atoms of Ala201, Gly118, and Gly119, as well as His440 Nε2 at the <scene name='2dfp/Cv/4'>active site</scene> of aged DFP-TcAChE ([[2dfp]]). Phosphorylation with DFP caused an unexpected distortion in the main chain of a loop that includes residues F288 and F290 of the TcAChE acyl binding pocket. F288 and F290 move significantly in the <font color='lime'><b>DFP-TcAChE structure (lime)</b></font>, in comparison to their positions in the <font color='magenta'><b>native enzyme</b></font> ([[2ace]]). This is the first major conformational change reported in the active site of any AChE−ligand complex, and it offers a structural explanation for the substrate selectivity of AChE.
DFP, di''iso''propylphosphorofluoridate, is an other toxic OP nerve agent. It is also inhibits AChE by covalent binding to the catalytic Ser200. As in the case with soman ([[1som]]) and sarin ([[1cfj]]), there are four hydrogen bond donors (dotted lines) to the anionic phosphonyl oxygen atoms: the backbone amide nitrogen atoms of Ala201, Gly118, and Gly119, as well as His440 Nε2 at the <scene name='2dfp/Cv/4'>active site</scene> of aged DFP-TcAChE ([[2dfp]]). Phosphorylation with DFP caused an unexpected distortion in the main chain of a loop that includes residues F288 and F290 of the TcAChE acyl binding pocket. F288 and F290 move significantly in the <font color='lime'><b>DFP-TcAChE structure (lime)</b></font>, in comparison to their positions in the <font color='magenta'><b>native enzyme</b></font> ([[2ace]]). This is the first major conformational change reported in the active site of any AChE−ligand complex, and it offers a structural explanation for the substrate selectivity of AChE.
{{Clear}}
{{Clear}}
 +
 +
 +
 +
'''For information about additional AChE monovalent inhibitors please see [[AChE inhibitors and substrates (Part II)]].'''
'''For information about additional AChE monovalent inhibitors please see [[AChE inhibitors and substrates (Part II)]].'''

Revision as of 11:35, 1 July 2010

Dear readers, this page presents only a small part of the great world of the acetylcholinesterase inhibitors. So, please see also our pages AChE inhibitors and substrates (Part II), AChE inhibitors and substrates (Part III), AChE bivalent inhibitors and AChE bivalent inhibitors (Part II).

Contents

AChE substrate

Drag the structure with the mouse to rotate

Solution of the three-dimensional (3D) structure of Torpedo californica acetylcholinesterase (TcAChE) in 1991 (Sussman et al. & Silman (1991)) opened up new horizons in research on an enzyme that had already been the subject of intensive investigation. The unanticipated structure of this extremely rapid enzyme, in which the active site was found to be buried at the bottom of a , lined by (colored dark magenta), led to a revision of the views then held concerning substrate traffic, recognition and hydrolysis (Botti et al. Sussman & Silman (1999)). This led to a series of theoretical and experimental studies, which took advantage of recent advances in theoretical techniques for treatment of proteins, such as molecular dynamics and electrostatics and to site-directed mutagenesis, utilizing suitable expression systems. Acetylcholinesterase hydrolysizes the neurotransmitter acetylcholine , producing group. directly binds (via its nucleophilic Oγ atom) within the catalytic triad (ACh/TcAChE structure 2ace). The residues are also important in the ligand recognition .

AChE monovalent inhibitors (Part I)

Organophosphorus acid anhydride nerve agents


Organophosphorus (OP) acid anhydride nerve agents are potent inhibitors which rapidly phosphonylate AChE and then may undergo an internal dealkylation reaction (called "aging") to produce an OP-enzyme conjugate that cannot be reactivated.

Reaction between Ser200Oγ and Soman, assuming an in-line attack by the Oγ, followed by spontaneous dealkylation of the O-pinacolyl group.
Reaction between Ser200Oγ and Soman, assuming an in-line attack by the Oγ, followed by spontaneous dealkylation of the O-pinacolyl group.


Drag the structure with the mouse to rotate

As was mentioned above, AChE hydrolysizes the neurotransmitter , producing group. directly binds catalytic (via its nucleophilic Oγ atom). , O-(1,2,2-trimethylpropyl) methylphosphonofluoridate (fluorine atom is colored violet and phosphorus atom is colored darkmagenta), is one of the most toxic OPs. Soman inhibits AChE by to catalytic Ser200, . This process implicates nucleophilic attack of the Ser200 nucleophilic Oγ atom on the phosphorus atom of soman, with concomitant departure of its fluoride atom. After that AChE catalyzes the of the soman or other OP. This causes irreversible inhibition of AChE, "aged" soman/AChE conjugate can not be reactivated. However, before “aging”, at the step of , AChE can be by nucleophiles, such as pralidoxime (2-PAM), resulting in of the phosphonyl adduct from Ser200 Oγ. At the (2wfz) the catalytic His440 forms hydrogen bonds with Ser200 Oγ and Glu327 Oε1 via its Nε2 and Nδ1 nitrogens, respectively. The O2 atom of soman is within hydrogen bonding distance of His440 Nε2. Soman O1 mimicks carbonyl oxygen of ACh. A water molecule 1001 interacting with soman O2 is represented as a red ball. The active site residues of the nonaged soman/TcAChE are colored yellow. The O2 atom of the (2wg0) forms a salt bridge with His440 Nε2. The active site residues of the aged soman/TcAChE are colored pink. of the structures of the nonaged (2wfz) and aged (2wg0) conjugates reveals a small, but important, change within the active site - the imidazole ring of His440 is tilted back to a native-like conformation after dealkylation. The water molecule 1001, which interacts with soman O2 in the nonaged crystal structure, is not within hydrogen bonding distance of O2 in the aged crystal structure. 2-PAM binds poorly to the nonaged phosphonylated enzyme (its electron density was not found) and binds in an after soman aging to TcAChE (2wg1).


1som, resolution 2.20Å

Drag the structure with the mouse to rotate

To understand the basis for irreversible inhibition, the structure of the aged conjugate obtained by reaction of TcAChE with soman was solved by X-ray crystallography to 2.2Å resolution (1som). The highest positive difference density peak corresponded to the OP phosphorus and was located within covalent bonding distance of the active-site serine (S200). The are within hydrogen-bonding distance of four potential donors from catalytic subsites of the enzyme, suggesting that electrostatic forces significantly stabilize the aged enzyme. The methyl group of soman occupies the , bounded by Trp233, Phe288, and Phe290.

PDB ID 1cfj.pdb

Drag the structure with the mouse to rotate

Sarin, O-isopropylmethylphosponofluoridate, is an other toxic OP compound. It is also inhibits AChE by covalent binding to the catalytic Ser200. The active sites of aged (1cfj) and aged soman-TcAChE (1som and 2wg0) are almost identical and provided structural models for the negatively charged, tetrahedral intermediate that occurs during deacylation with the ACh. There are four hydrogen bond donors (red dotted lines) to the anionic phosphonyl oxygen atoms: the backbone amide nitrogen atoms of Ala201, Gly118, and Gly119, as well as His440 Nε2. The sarin methyl carbon (colored cyan) is within non-bonded contact distances (black dotted lines) of Phe288 and Phe290 in the acyl binding pocket.

Drag the structure with the mouse to rotate

DFP, diisopropylphosphorofluoridate, is an other toxic OP nerve agent. It is also inhibits AChE by covalent binding to the catalytic Ser200. As in the case with soman (1som) and sarin (1cfj), there are four hydrogen bond donors (dotted lines) to the anionic phosphonyl oxygen atoms: the backbone amide nitrogen atoms of Ala201, Gly118, and Gly119, as well as His440 Nε2 at the of aged DFP-TcAChE (2dfp). Phosphorylation with DFP caused an unexpected distortion in the main chain of a loop that includes residues F288 and F290 of the TcAChE acyl binding pocket. F288 and F290 move significantly in the DFP-TcAChE structure (lime), in comparison to their positions in the native enzyme (2ace). This is the first major conformational change reported in the active site of any AChE−ligand complex, and it offers a structural explanation for the substrate selectivity of AChE.



For information about additional AChE monovalent inhibitors please see AChE inhibitors and substrates (Part II).

AChE bivalent inhibitors

Please see pages AChE bivalent inhibitors and AChE bivalent inhibitors (Part II)

Selected 3D Structures of AChE

  • 2ace This is the original solved structure for Torpedo Californica
  • 1ea5 This is one of the highest quality representative X-ray structures in the PDB.
  • 1eve The E2020 (Aricept) complex.
  • 1ax9 Endrophonium complex.
  • 1vot Complex with Huperzine, a Chinese folk medicine.
  • 1fss Complex with snake venum toxin Fasciculin-II.
  • 1acj Complex with tacrine.
  • 1e66 Complex with huprine X.
  • 1dx6 Complex with galanthamine.
  • 1qti Complex with galanthamine.
  • 1w6r Complex with galanthamine iminium derivative.
  • 2ack Complex with edrophonium.
  • 1vzj Structure of the tetramerization domain of acetylcholinesterase.
  • 1gqr Complex with rivastigmine.
  • 1gqs Complex with NAP alone.
  • 1vxr Complex with VX.
  • 2vja Complex with OTMA.
  • 1som Complex with soman.
  • 2wfz Complex with nonaged soman.
  • 2wg0 Complex with aged soman.
  • 2wg1 Complex with aged soman and 2-PAM.
  • 1cfj Complex with aged sarin.
  • 2dfp Complex with aged DFP.


More structures can be obtained by searching for AChE

References




  • Raves ML, Harel M, Pang YP, Silman I, Kozikowski AP, Sussman JL. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat Struct Biol. 1997 Jan;4(1):57-63. PMID:8989325
  • Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9031-5. PMID:8415649
  • Greenblatt HM, Guillou C, Guenard D, Argaman A, Botti S, Badet B, Thal C, Silman I, Sussman JL. The complex of a bivalent derivative of galanthamine with torpedo acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design. J Am Chem Soc. 2004 Dec 1;126(47):15405-11. PMID:15563167 doi:http://dx.doi.org/10.1021/ja0466154
  • Ravelli RB, Raves ML, Ren Z, Bourgeois D, Roth M, Kroon J, Silman I, Sussman JL. Static Laue diffraction studies on acetylcholinesterase. Acta Crystallogr D Biol Crystallogr. 1998 Nov 1;54(Pt 6 Pt 2):1359-66. PMID:10089512
  • Haviv H, Wong DM, Greenblatt HM, Carlier PR, Pang YP, Silman I, Sussman JL. Crystal packing mediates enantioselective ligand recognition at the peripheral site of acetylcholinesterase. J Am Chem Soc. 2005 Aug 10;127(31):11029-36. PMID:16076210 doi:http://dx.doi.org/10.1021/ja051765f
  • Carlier PR, Du DM, Han Y, Liu J, Pang YP. Potent, easily synthesized huperzine A-tacrine hybrid acetylcholinesterase inhibitors. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2335-8. PMID:10476864
  • Wong DM, Greenblatt HM, Dvir H, Carlier PR, Han YF, Pang YP, Silman I, Sussman JL. Acetylcholinesterase complexed with bivalent ligands related to huperzine a: experimental evidence for species-dependent protein-ligand complementarity. J Am Chem Soc. 2003 Jan 15;125(2):363-73. PMID:12517147 doi:http://dx.doi.org/10.1021/ja021111w
  • Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science. 1991 Aug 23;253(5022):872-9. PMID:1678899
  • Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6. PMID:10606746
  • Bar-On P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, Silman I. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry. 2002 Mar 19;41(11):3555-64. PMID:11888271
  • Colletier JP, Bourgeois D, Sanson B, Fournier D, Sussman JL, Silman I, Weik M. Shoot-and-Trap: use of specific x-ray damage to study structural protein dynamics by temperature-controlled cryo-crystallography. Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11742-7. Epub 2008 Aug 13. PMID:18701720
  • Dvir H, Wong DM, Harel M, Barril X, Orozco M, Luque FJ, Munoz-Torrero D, Camps P, Rosenberry TL, Silman I, Sussman JL. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates. Biochemistry. 2002 Mar 5;41(9):2970-81. PMID:11863435
  • Millard CB, Kryger G, Ordentlich A, Greenblatt HM, Harel M, Raves ML, Segall Y, Barak D, Shafferman A, Silman I, Sussman JL. Crystal structures of aged phosphonylated acetylcholinesterase: nerve agent reaction products at the atomic level. Biochemistry. 1999 Jun 1;38(22):7032-9. PMID:10353814 doi:http://dx.doi.org/10.1021/bi982678l
  • Sanson B, Nachon F, Colletier JP, Froment MT, Toker L, Greenblatt HM, Sussman JL, Ashani Y, Masson P, Silman I, Weik M. Crystallographic Snapshots of Nonaged and Aged Conjugates of Soman with Acetylcholinesterase, and of a Ternary Complex of the Aged Conjugate with Pralidoxime (dagger). J Med Chem. 2009 Jul 30. PMID:19642642 doi:10.1021/jm900433t
Personal tools